Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 11/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Filociclovir SCHEMBL1337940 | 0.82 | TK1 (0.49) | ADORA3HPRT1ALDH1A1LMNAPNP | |
| Filociclovir SCHEMBL1335812 | 0.82 | TK1 (0.49) | ADORA3HPRT1ALDH1A1LMNAPNP | |
| Filociclovir SCHEMBL1335817 | 0.82 | TK1 (0.49) | ADORA3HPRT1ALDH1A1LMNAPNP | |
| SCHEMBL1336821 | 0.77 | KDM4E (0.52) | ADORA3LMNA | |
| SCHEMBL1338091 | 0.77 | KDM4E (0.52) | ADORA3LMNA | |
| SCHEMBL1338323 | 0.74 | HDAC6 (0.38) | — | |
| SCHEMBL1337381 | 0.74 | HDAC6 (0.38) | — | |
| SCHEMBL1337383 | 0.74 | HDAC6 (0.38) | — | |
| SCHEMBL1337727 | 0.73 | CDK1 (0.43) | ADORA3LMNA | |
| SCHEMBL21340782 | 0.73 | PNP (0.43) | ADORA3HPRT1ALDH1A1LMNAPNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298256-A1 | ANTIVIRAL COMPOUNDS | EPIPHANY BIOSCIENCES, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298256-A1 | ANTIVIRAL COMPOUNDS | EPIPHANY BIOSCIENCES, INC. | 2010-11-25 | — | — | US | disclosed |
| WO-2009085267-A1 | ANTIVIRAL COMPOUNDS | EPIPHANY BIOSCIENCES (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298256-A1 | ANTIVIRAL COMPOUNDS | MTAP, PNP, TYMP | ADORA3 689/4885HPRT1 26/4885ALDH1A1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.